Gates Foundation will provide $120 million to ensure generic production of Merck’s Covid-19 pill
Stat - 10/20/2021
This suggests Merck will profit handsomely from sales to wealthy nations, but its licensing deals will not ensure sufficient access, according to Brook Baker, a Northeastern University professor who specializes in access to medicines and intellectual property and a senior policy analyst for Health GAP.
“There are three positives here: more efficient manufacturing that can lead to a cheaper price, expediting regulatory approval processes in countries, and the WHO prequalification, and the volume guarantees to incentivize production,” he said. “Depending on how contracts are worded, they may encourage companies to start making at risk, which means before regulatory approval.”